We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA FINALIZES RULES FOR INDEPENDENT REVIEWS OF BIOTECH DRUGS
FDA FINALIZES RULES FOR INDEPENDENT REVIEWS OF BIOTECH DRUGS
August 18, 2004
The FDA has released a guidance document that instructs clinical trial sponsors on when and how to request that the agency engage an independent consultant to participate in reviewing clinical studies, which serve as the primary basis of efficacy claims.